Maraviroc Waymade

Maraviroc, the active ingredient in Maraviroc Waymade, is a CCR5 antagonist presented as an oral formulation for oral use. It is indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents, targeting patients with CCR5‑tropic virus.

GNH USA supplies Maraviroc Waymade as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand.

Maraviroc is a CCR5 antagonist used in the management of HIV‑1 infection, a viral disease that targets the immune system.

- HIV‑1 infection: Used in combination with other antiretroviral agents to suppress viral replication in patients with CCR5‑tropic virus. - Treatment‑experienced HIV: Provides an additional option for patients who have developed resistance to other antiretroviral classes. - Combination antiretroviral therapy: Enhances overall treatment efficacy when paired with nucleoside reverse transcriptase inhibitors and protease inhibitors.

Maraviroc may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Headache: mild to moderate headache reported in clinical studies. - Nausea: occasional nausea or upset stomach. - Diarrhea: loose stools or increased bowel movements. - Fatigue: general tiredness or lack of energy.

Serious or Rare Side Effects: - Liver injury: signs of hepatitis or elevated liver enzymes. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Depression or suicidal thoughts: new or worsening mood changes. - Cardiovascular events: chest pain, arrhythmia, or hypertension.

When prescribing Maraviroc, clinicians should observe several precautionary measures to ensure patient safety. - Liver function monitoring: assess hepatic enzymes before and during therapy. - Cardiovascular assessment: evaluate history of heart disease prior to initiation. - Mental health screening: monitor for depression or suicidal ideation throughout treatment. - Hypersensitivity caution: discontinue if signs of severe allergic reaction appear. - Pregnancy and breastfeeding: use only if potential benefit justifies potential risk, as safety data are limited. - Store at room temperature: keep in original container, protect from moisture and direct sunlight.

Maraviroc can interact with other medicines, affecting its concentration and therapeutic effect.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ritonavir, clarithromycin): may increase Maraviroc levels and risk of toxicity. - Potent CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce drug exposure and compromise efficacy. - Certain antiretroviral boosters (e.g., cobicistat): can markedly elevate plasma concentrations.

Moderate Interactions (Monitor Closely): - Statins metabolized by CYP3A4 (e.g., simvastatin, atorvastatin): may require dose adjustment. - Anticoagulants (e.g., warfarin): monitor INR for potential changes. - Other antiretrovirals (e.g., efavirenz): may modestly affect Maraviroc levels. - Herbal supplements (e.g., St. John’s wort): can induce metabolism and lower drug exposure.